140 related articles for article (PubMed ID: 8879766)
1. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Griffith J; Werner BG
Clin Infect Dis; 1996 Sep; 23(3):468-74. PubMed ID: 8879766
[TBL] [Abstract][Full Text] [Related]
2. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
George MJ; Snydman DR; Werner BG; Griffith J; Falagas ME; Dougherty NN; Rubin RH
Am J Med; 1997 Aug; 103(2):106-13. PubMed ID: 9274893
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; George MJ; Werner B; Ruthazer R; Griffith J; Rohrer RH; Freeman R
Transplantation; 1996 Jun; 61(12):1716-20. PubMed ID: 8685949
[TBL] [Abstract][Full Text] [Related]
5. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Griffith J; Ruthazer R; Werner BG
Ann Intern Med; 1997 Feb; 126(4):275-9. PubMed ID: 9036799
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rubin RH; Dienstag JL; Rohrer RH; Freeman R; Jenkins R; Lewis WD; Hammer S; O'Rourke E; Grady GF; Fawaz K; Kaplan MM; Hoffman MA; Katz AT; Doran M;
Ann Intern Med; 1993 Nov; 119(10):984-91. PubMed ID: 8214995
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis.
Arbo MD; Snydman DR; Wong JB; Goldberg HS; Schmid CH; Pauker SG
Clin Transplant; 2000 Feb; 14(1):19-27. PubMed ID: 10693631
[TBL] [Abstract][Full Text] [Related]
8. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
9. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG
Clin Infect Dis; 1996 Aug; 23(2):292-7. PubMed ID: 8842266
[TBL] [Abstract][Full Text] [Related]
10. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Infect Dis; 1997 Aug; 25(2):314-7. PubMed ID: 9332531
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?
Bruminhent J; Thongprayoon C; Dierkhising RA; Kremers WK; Theel ES; Razonable RR
Liver Transpl; 2015 Apr; 21(4):539-46. PubMed ID: 25597303
[TBL] [Abstract][Full Text] [Related]
12. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
[TBL] [Abstract][Full Text] [Related]
13. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
[No Abstract] [Full Text] [Related]
14. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients.
Munoz-Price LS; Slifkin M; Ruthazer R; Poutsiaka DD; Hadley S; Freeman R; Rohrer R; Angelis M; Cooper J; Fairchild R; Barefoot L; Bloom J; Fitzmaurice S; Snydman DR
Clin Infect Dis; 2004 Nov; 39(9):1293-9. PubMed ID: 15494905
[TBL] [Abstract][Full Text] [Related]
15. Donated organ as a source of cytomegalovirus in orthotopic liver transplantation.
Sutherland S; Bracken P; Wreghitt TG; O'Grady J; Calne RY; Williams R
J Med Virol; 1992 Jul; 37(3):170-3. PubMed ID: 1331304
[TBL] [Abstract][Full Text] [Related]
16. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.
Falagas ME; Paya C; Ruthazer R; Badley A; Patel R; Wiesner R; Griffith J; Freeman R; Rohrer R; Werner BG; Snydman DR
Transplantation; 1998 Oct; 66(8):1020-8. PubMed ID: 9808486
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
19. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients.
DesJardin JA; Cho E; Supran S; Gibbons L; Werner BG; Snydman DR
Clin Infect Dis; 2001 Oct; 33(8):1358-62. PubMed ID: 11565077
[TBL] [Abstract][Full Text] [Related]
20. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG-Study Group.
George MJ; Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD
Transplant Proc; 1993 Oct; 25(5 Suppl 4):22-4. PubMed ID: 8212303
[No Abstract] [Full Text] [Related]
[Next] [New Search]
